US Patent

US12390419 — Formulations of (R)-2-amino-3-phenylpropyl carbamate

Method of Use · Assigned to Axsome Malta Ltd · Expires 2037-09-05 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate, also known as solriamfetol hydrochloride, for treating disorders.

USPTO Abstract

The present invention relates to immediate release formulations of (R)-2-amino-3-phenylpropyl carbamate and methods of using the same to treat disorders.

Drugs covered by this patent

solriamfetol-hydrochloride (SOLRIAMFETOL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2548`	—	solriamfetol-hydrochloride
`U-2548`	—	solriamfetol-hydrochloride

Patent Metadata

Patent number: US12390419
Jurisdiction: US
Classification: Method of Use
Expires: 2037-09-05
Drug substance claim: No
Drug product claim: Yes
Assignee: Axsome Malta Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.